Fool - Investing News
04 Jun 2026, 06:30 UTC · 3h ago
Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer?
Search tags
Fool - Investing News
04 Jun 2026, 06:30 UTC · 3h ago
Search tags
Story key points
3 claims · impact-rated
Pfizer's dividend payout ratio exceeds 60%, which is described as being on the cusp of being unsustainable for long-term growth and debt management. — Higher payout ratios increase the risk of dividend cuts, which typically triggers significant sell-offs in income-focused stocks.
-0.40Analyst forecasts project declining sales for both Pfizer (down 1.4% this year) and Bristol Myers Squibb (down 1.8% to 2.3% in 2026-2027). — Consistent negative sales forecasts indicate a lack of top-line growth, putting downward pressure on stock valuations.
-0.30Bristol Myers Squibb maintains a lower payout ratio of approximately 40% and a higher average annual dividend growth rate (5.3%) compared to Pfizer (4.4%). — Stronger dividend durability and growth make the stock more attractive to long-term defensive investors.
+0.20Ticker attribution
Continue reading
6 related stories
Model heads
The company is praised for its healthier dividend payout ratio, superior dividend growth, and better sustainability compared to Pfizer.
The author expresses concerns regarding the sustainability of its high dividend yield, a higher payout ratio, and forecasted sales declines.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
0 dimensions · 9 clusters
No impact vector found for this article yet.
Market reaction
0 bid · 0 offered
No stock impact ranking available yet.
No stock impact ranking available yet.
Globe News Wire
2h ago
